Leaders are worried some of the sector’s persistent challenges — like finance pressures and worker burnout — could worsen ...

Researchers said the results suggest UnitedHealth may be sidestepping government rules meant to keep a lid on exorbitant ...

Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara ...

The hospital operator will invest more in organic hospital growth and high-acuity service lines as it sees strong demand for ...

Dr. Cliff Deveny announced the transition less than a month after General Catalyst finalized its $515 million acquisition of Summa.

Former Congressional Budget Office Director Dan Crippen argues the 340B discount program is overdue for reform.

Overall, Cigna expects earnings to grow next year after posting a solid third quarter. But investments in a new PBM model and ...

The goodwill impairment charge is meant to realign Centene’s value on its own books with its value in the market, which has ...

The healthcare giant beat Wall Street expectations in the third quarter, but reported a net loss after recording a $5.7 ...

The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help ...

The company has started to score insurers on their success in making rate data available online. Large payers tend to do ...

The $600 million deal was foreshadowed during the company’s third quarter earnings call this month, when CEO Kevin Hammons ...